ChemGenex’s metabolic disease assets currently reside within the company’s wholly-owned subsidiary Autogen Research, which is to be renamed Verva Pharmaceuticals. Pending shareholder approval at the annual general meeting,
Findings from trial of obese, but otherwise healthy, adults demonstrated that adults taking 600mg of drug twice-daily (n=11) for 28 days lost an average of 0.45 kg (1
In the SWEET (simplification with easier emtricitabine and tenofovir) study, patients who switched from Combivir to Truvada, both in combination with once-daily Sustiva (efavirenz), experienced improvements in a
As part of this action, Cathleen Davis, the company’s vice president, finance and controller and Kevin Kaster, the company’s senior vice president, corporate development will leave the company.
Pursuant to the terms of the termination agreement, King has paid Depomed termination and other fees of approximately $30 million, and Depomed will not pay King a promotion
Cardica, a provider of automated anastomosis systems for coronary artery bypass graft surgery, will not receive any proceeds from sales of shares made by the selling stockholder and
Medical device maker Insulet has granted the underwriters the right to purchase up to an additional 734,759 shares to cover over-allotments, if any. Insulet will not receive any
All of IsoTis’s outstanding $12.6 million in debt was repaid at closing. Integra, which focuses on advanced technology in orthobiologics, intends to integrate both IsoTis’s domestic network of
The new Phase I single-dose, dose-escalation trial with MDX-1106 (ONO-4538) is expected to enroll up to 34 patients with active hepatitis C genotype I infection (HCV). The study
Epicel is the first xenotransplantation-classified product to be approved in the US because of its inclusion of animal cells. It is a product that can provide permanent skin
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.